The antimicrobial susceptibility of Helicobacter pylori strains isolated from children and adults with primary infection in the Lower Silesia region, Poland

• Autorzy: Gosciniak G. , Biernat M. , Grabinska J. , Binkowska A. , Poniewierka E. , Iwanczak B.
• Języki publikacji: EN

Abstrakty

EN

The resistance of microorganisms to antibiotics has become a serious issue in recent years in the therapy of bacterial infections. This problem also concerns the treatment of infections caused by Helicobacter pylori strains. The aim of this study was to evaluate the frequency of primary resistance of H. pylori strains isolated from children and adults. The subject of the research was 105 strains of H. pylori isolated from children and 60 strains from adults in the Lower Silesia Region in the years 2008–2011. Antimicrobial susceptibility to the following antibiotics was assessed: amoxicillin (AC), clarithromycin (CH), metronidazole (MZ), tetracycline (TC), levofloxacin (LEV) and rifabutin (RB). Among the strains isolated from children, 33.3% were resistant to CH, 44.8% to MZ whereas 1.9% of strains were resistant simultaneously to CH, MZ and LEV. Among 60 strains isolated from adults, 23.3% were resistant to CH, 66.7% to MZ, and 6.7% to LEV. Moreover, 16 multidrug resistant strains were isolated from adults, including 12 resistant to CH and MZ, 3 to MZ and LEV, and 1 to CH, MZ and LEV. All examined strains were susceptible to AC, TC and RB. The high incidence of resistance to CH and MZ suggests that standard triple therapies may not be useful as first-line treatment in Poland without earlier susceptibility testing.

Słowa kluczowe

EN

antimicrobial susceptibility; Helicobacter pylori; isolation; child; adult; resistance; primary infection; Lower Silesian region; Poland

• Wydawca: -
• Czasopismo: Polish Journal of Microbiology
• Rocznik: 2014
• Tom: 63
• Numer: 1
• Opis fizyczny: p.57-61,fig.,ref.

Twórcy

autor

Gosciniak G.

• Department of Microbiology, Wroclaw Medical University, Chalubinskiego Street 4, 50-368 Wroclaw, Poland

autor

Biernat M.

• Department of Microbiology, Wroclaw Medical University, Chalubinskiego Street 4, 50-368 Wroclaw, Poland

autor

Grabinska J.

• Department of Microbiology, Wroclaw Medical University, Chalubinskiego Street 4, 50-368 Wroclaw, Poland

autor

Binkowska A.

• Department of Microbiology, Wroclaw Medical University, Chalubinskiego Street 4, 50-368 Wroclaw, Poland

autor

Poniewierka E.

• Department and Clinic of Gastroenterology and Hepatology, Wroclaw Medical University, Wroclaw, Poland

autor

Iwanczak B.

• IInd Department and Clinic of Pediatric Gastroenterology and Nutrition, Wroclaw Medical University, Wroclaw, Poland

Bibliografia

• Andrzejewska E., A. Szkaradkiewicz and T. Karpiński. 2009. Antimicrobial resistance of Helicobacter pylori clinical strains in the last 10 years. Pol. J. Microbiol. 4: 301–305.
• Aqudo S., T. Alarcon, L. Cibrelus, P. Urruzuno, M.J. Martinez and M. Lopez-Brea. 2009. High percentage of clarithromycin and metronidazole resistance in Helicobacter pylori clinical isolates obtained from Spanish children. Rev. Esp. Quimioter. 22: 88–92.
• Bąk-Romaniszyn L. and I. Płaneta-Małecka. 2004. Przyczyny niepowodzenia eradykacji zakażenia Helicobacter pylori. Ped. Wsp. Gastroenterol Hep. Żyw. Dziecka 4: 387–392.
• Boyanova L. 2009. Prevalence of multidrug-resistant Helicobacter pylori in Bulgaria. J. Med. Microbiol. 58: 930–935.
• Boyanova L. and I. Mitov. 2010. Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents. Expert Rev. Anti. Infect. Ther. 8: 59–70.
• Da Silva Mendeiros J.A, T.M.F.O. Goncalves, L. Boyanova,M.I. de Correia Pereira, J.N. da Silva Paiva de Carvalho,A.M. de Sousa Pereira, and A.M. Silverio Carbita. 2011. Evaluation of Helicobacter pylori eradication by triple therapy plus Lactobacillus acidophilus compared to triple therapy alone. Eur. J. Clin. Microbiol. Infect. Dis. 30: 555–559.
• De Francesco V., F. Georgio, C. Hassan, G. Manes, L. Vannella,C. Panella, E. Ierardi, and A. Zullo. 2010. Worldwide H. pylori antibiotic resistance: a systematic review. J. Gastointestin. Liver Dis. 19: 409–414.
• Dzierżanowska-Fangrat K., E. Rożynek, D. Celińska-Cedro,P. Jóźwiak, K. Madaliński and D. Dzierżanowska. 2002. Primary resistance of H. pylori to antimicrobial agents in Polish children. Acta Micriobiol. Pol. 51: 255–263.
• Dzierżanowska-Fangrat K., E. Rożynek, D. Celińska-Cedro,M. Jarosz, J. Pawłowska, A. Szadkowski, A. Budzyńska, J. Nowak,W. Romańczuk, R. Prosiecki and others. 2005. Antimicrobial resistance of Helicobacter pylori in Poland: a multicenter study. Int.J. Antimicrob. Agents 26: 230–234.
• Elviss N.C., R. J. Owen, J. Xerry, A.M. Walker and K. Davies. 2004. Helicobacter pylori antibiotic resistance patterns and genotypes in adult dyspeptic patients from a regional population in North Wales. J. Antimicrob. Chemioter. 54: 435–440.
• Gisbert J.P. and X. Calvet. 2012. Rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment. Pharmacol. Ther. 35: 209–221.
• Glupczynski Y., F. Megraud, M. Lopez-Brea and L.P. Andersen. 2001. European multicenter survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur. J. Clin. Microbiol. Infect. Dis. 20: 820–823.
• Glupczynski Y, N. Broutet, A. Cantagrel, L.P. Andersen, T. Alarcon, M. Lopez-Brea and F. Megraud. 2002. Comparison of the E-test and agar dilution method for antimicrobial susceptibility testing of Helicobacter pylori. Eur. J. Clin. Microbiol. Infect. Dis. 21: 549–552.
• Gościniak G. Y. Glupczyński, S. Goutier, C. Van Den Borre,J.P. Butzler and A. Przondo-Mordarska. 1998. Prevalence of antibiotic resistance in Helicobacter pylori strains in Poland. Clin. Microbial. Infect. 12: 726–728.
• Gościniak G., B. Iwańczak, A. Przondo-Mordarska, J. Grabińska and F. Iwańczak. 2004. High Level of resistance to metronidazole and clarithromycin in Helicobacter pylori isolated from pediatric patients in Poland. Folia Microbiol. 49: 133–136.
• Graham D.Y. and A. Shiotani. 2008. New concepts of resistance in the treatment of Helicobacter pylori infections. Nature Clin. Practice Gastroenterol. Hepatol. 5: 321–331.
• Kadayifci A., Buyukhatipoglu H., Cemil Savas M. and I. Simsek. 2006. Eradication of Helicobacter pylori with triple therapy: an epidemiologic analysis of trends in Turkey over 10 years. Clin. Ther. 28: 1960–1966.
• Karczewska E, I. Wojtas-Bonior, E. Sito, M. Zwolińska-Wcisło and A. Budak. 2011. Primary and secondary clarithromycin, metronidazole, amoxicillin and levofloxacin resistance to Helicobacter pylori in southern Poland. Pharmacol. Rep. 63: 799–807.
• Karczewska E., K. Klesiewicz, I. Skiba, I. Wojtas-Bonior, E. Sito, K. Czajecki, M. Zwolińska-Wcisło and A. Budak. 2012. Variability in prevalence of Helicobacter pylori strains resistant to clarithromycin and levofloxacin in Southern Poland. Gastroenterol. Res. Pract. doi: 10.1155/2012/418010.
• Łaszewicz W. 2003. H. pylori infection in Poland – epidemiological stu-dy in children and adults (in Polish). Acad. Med. Bialostocensis 30–39.
• Megraud F. 2004. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 53: 1374–1384.
• Megraud F. and P. Lehours. 2007. Helicobacter pylori detection andantimicrobial susceptibility testing. Clin. Microbiol. Rev. 20: 280–322.
• Megraud F., S. Coenen, A. Versporten, M. Kist, M. Lopez-Brea, A.M. Hirschl, L.P. Andersen, H. Goossens, Y. Glupczynski on behalf of the Study Group participants. 2013. Helicobacter pylori resistance to antibiotic in Europe and its relationship to antibiotic consumption. Gut 62: 34–42.
• Mishra S. 2012. Is Helicobacter pylori good or bad? Eur. J. Clin. Microbiol. Infect. Dis. Doi: 10.1007/s10096-012-1773-9.
• Nishizawa T., H. Suzuki, J. Matsuzaki, H. Muraoka, H. Tsuqawa, K. Hirata and T. Hibi. 2011. Helicobacter pylori resistance to rifabutin in the last 7 years. Antimicrob. Agents Chem. 55: 5374–5375.
• Selgrad M. and P. Malfertheiner. 2011. Treatment of Helicobacter pylori. Curr. Opin. Gastroenterol. 27: 565–570.
• Yang J.C., P.I. Lee and P.R. Hsueh. 2010. In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998–2007. Eur. J. Clin. Microbiol. Infect. Dis. 29: 1369–75.